Docstoc

EYEGATE PHARMA TO PRESENT AT UPCOMING INVESTOR CONFERENCES

Document Sample
EYEGATE PHARMA TO PRESENT AT UPCOMING INVESTOR CONFERENCES Powered By Docstoc
					IR/PR Contact:
Tim Allison
LaVoie Group
978-745-4200 X 102
tallison@lavoiegroup.com


FOR IMMEDIATE RELEASE:

                      EYEGATE PHARMA TO PRESENT AT
                     UPCOMING INVESTOR CONFERENCES
Waltham, MA, – April 15, 2008 – EyeGate Pharma, a privately held, specialty pharmaceutical
company using iontophoresis technology to safely and non-invasively deliver therapeutics into
the front and back of the eye for treating serious ocular diseases, today announced that
Stephen From, President and CEO of EyeGate, will present at the First Annual BIO National
Venture Conference and the Rodman and Renshaw 5th Annual Global Healthcare
Conference. Mr. From will be available for one-on-one meetings during both conferences.

The First Annual BIO National Venture Conference will take place on April 22-23, 2008 at the
Hyatt Regency Cambridge with Stephen From’s presentation taking place on April 22 at 3:45
PM. For more information, please visit http://bnvc.bio.org/opencms/BioVenture/2008/index.jsp

Stephen From will also present at the Rodman and Renshaw 5th Annual Global Healthcare
Conference taking place May 19-20, 2008 at Le Meridien Beach Plaza Hotel at the Sea Club,
with his presentation taking place on May 19, at 9:20 AM in the Zephyr Salon (4th floor). For
more information, please visit http://www.rodmanandrenshaw.com/conferences?id=18

About EyeGate Pharma
EyeGate Pharma was founded in 1999 with technology licensed from Bascom Palmer Eye
Institute at the University of Miami. EyeGate’s transscleral (across the sclera, or white
protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate® II
Delivery System, was developed to safely deliver a wide range of therapeutics to both the
anterior (front) and posterior (back) chambers of the eye. An 89-patient clinical study, using
the company’s first-generation delivery device, demonstrated significant decreases in
inflammatory markers and concurrent increases in visual acuity. A typical application takes
less than five minutes and has been shown to be extremely well tolerated in patients suffering
from severe uveitis and other inflammatory ocular diseases. Clinical studies utilizing the
EyeGate® II Delivery System are scheduled to begin in the first half of 2008. For more
information please visit www.eyegatepharma.com.
                                            # # #

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:14
posted:12/18/2011
language:
pages:1